ATE543497T1 - SUBSTITUTED HETEROCYCLIC DERIVATIVES AS AGENT AGAINST DIABETES AND OBESITY AND METHODS - Google Patents

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS AGENT AGAINST DIABETES AND OBESITY AND METHODS

Info

Publication number
ATE543497T1
ATE543497T1 AT03763345T AT03763345T ATE543497T1 AT E543497 T1 ATE543497 T1 AT E543497T1 AT 03763345 T AT03763345 T AT 03763345T AT 03763345 T AT03763345 T AT 03763345T AT E543497 T1 ATE543497 T1 AT E543497T1
Authority
AT
Austria
Prior art keywords
obesity
methods
substituted heterocyclic
agent against
heterocyclic derivatives
Prior art date
Application number
AT03763345T
Other languages
German (de)
Inventor
Peter Cheng
Sean Chen
Charles Ding
Timothy Herpin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE543497T1 publication Critical patent/ATE543497T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds are provided which are useful as antidiabetic agents and antiobesity agents and have the structure wherein m is 0, 1 or 2; n is 0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1 where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is -(CH2)x2-O-(CH2)x3- where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH; X2 is N; X3 is C; X4 is N; X5 is C; X6 is C.
AT03763345T 2002-07-09 2003-07-08 SUBSTITUTED HETEROCYCLIC DERIVATIVES AS AGENT AGAINST DIABETES AND OBESITY AND METHODS ATE543497T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39455302P 2002-07-09 2002-07-09
PCT/US2003/021331 WO2004004655A2 (en) 2002-07-09 2003-07-08 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number Publication Date
ATE543497T1 true ATE543497T1 (en) 2012-02-15

Family

ID=30115733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763345T ATE543497T1 (en) 2002-07-09 2003-07-08 SUBSTITUTED HETEROCYCLIC DERIVATIVES AS AGENT AGAINST DIABETES AND OBESITY AND METHODS

Country Status (23)

Country Link
US (2) US6875782B2 (en)
EP (1) EP1531810B1 (en)
JP (1) JP4541883B2 (en)
KR (1) KR101120337B1 (en)
CN (1) CN1665500A (en)
AT (1) ATE543497T1 (en)
AU (1) AU2003248861B2 (en)
BR (1) BR0312503A (en)
CA (1) CA2490972C (en)
ES (1) ES2380319T3 (en)
GE (1) GEP20084475B (en)
HR (1) HRP20050001A2 (en)
IL (1) IL165809A (en)
IS (1) IS7629A (en)
MX (1) MXPA05000279A (en)
NO (1) NO329328B1 (en)
NZ (1) NZ537251A (en)
PL (1) PL375230A1 (en)
RS (1) RS20050002A (en)
RU (1) RU2325381C2 (en)
UA (1) UA79296C2 (en)
WO (1) WO2004004655A2 (en)
ZA (1) ZA200500029B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050026091A (en) * 2002-08-01 2005-03-14 뉴로서치 에이/에스 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
AR044503A1 (en) 2003-03-18 2005-09-14 Merck & Co Inc TRIAZOLS REPLACED WITH BIARILO AS BLOCKERS OF THE SODIUM CHANNEL
FR2861301B1 (en) * 2003-10-24 2008-07-11 Sanofi Synthelabo USE OF THE PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME.
FR2861302A1 (en) * 2003-10-24 2005-04-29 Sanofi Synthelabo Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks and dyslipidemia associated with obesity
FR2861303A1 (en) * 2003-10-24 2005-04-29 Sanofi Synthelabo Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity
FR2861300B1 (en) * 2003-10-24 2008-07-11 Sanofi Synthelabo USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME
JP2007512359A (en) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド Novel phosphorus-containing thyroid hormone-like substance
PT1725234E (en) 2004-03-05 2013-03-04 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
ZA200610650B (en) * 2004-05-25 2009-04-29 Metabolex Inc Substituted triazoles as modulators of PPAR and methods of their preparation
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2006032042A2 (en) * 2004-09-15 2006-03-23 Regeneron Pharmaceuticals, Inc. Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006117743A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
RU2007148927A (en) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) NEW TYREOMIMETICS CONTAINING PHOSPHIC ACID
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
FR2889191A1 (en) * 2005-07-28 2007-02-02 Cerep Sa COMPOUNDS DERIVED FROM 5-BENZYLIDENE IMIDAZOLIDINE 2,4-DIONE AND THEIR USE AS MCHR-1 ANTAGONISTS
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2006304689A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
US8084478B2 (en) * 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
CA2651663A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2673290A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103694195B (en) * 2013-09-18 2016-04-06 华东师范大学 Aromatic heterocyclic small molecular organic compounds and derivative, preparation method and medicinal use
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
JP2020500199A (en) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド Methods of treating glycogen storage disease
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
KR101943382B1 (en) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 A pharmaceutical composition comprising SGLT-2 inhibitor and angiotensin receptor blocker
AU2019238090A1 (en) 2018-03-22 2020-10-08 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
KR102131359B1 (en) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 A pharmaceutical composition with an improved stability

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018130A1 (en) 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
AU701776B2 (en) * 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JP3537446B2 (en) 1995-06-15 2004-06-14 明治製菓株式会社 Tricyclic benzazepine compounds
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (en) * 1996-04-03 2001-10-02 日本たばこ産業株式会社 Propionic acid derivatives and uses thereof
JPH1067759A (en) 1996-06-20 1998-03-10 Sankyo Co Ltd Herbicidal azole derivative
JPH11263775A (en) 1997-09-08 1999-09-28 Sankyo Co Ltd Hydroxyaniline derivative
NZ503601A (en) 1997-09-29 2002-02-01 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives for use as antiallergic medicaments
KR100620337B1 (en) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 Carboxylic acid derivatives and drugs containing the same as the active ingredient
FR2778314B1 (en) 1998-05-07 2002-06-14 Rhone Poulenc Agrochimie SYNERGISTIC FUNGICIDE COMPOSITION COMPRISING A STROBILURIN-LIKE COMPOUND
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6506781B1 (en) 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
TW200528436A (en) * 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
KR100518142B1 (en) 1999-11-10 2005-10-04 다케다 야쿠힌 고교 가부시키가이샤 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US7507757B2 (en) 2009-03-24
NZ537251A (en) 2007-02-23
US6875782B2 (en) 2005-04-05
KR101120337B1 (en) 2012-02-29
GEP20084475B (en) 2008-09-10
JP4541883B2 (en) 2010-09-08
EP1531810A2 (en) 2005-05-25
IS7629A (en) 2005-01-05
UA79296C2 (en) 2007-06-11
CA2490972A1 (en) 2004-01-15
US20040063762A1 (en) 2004-04-01
ES2380319T3 (en) 2012-05-10
RU2325381C2 (en) 2008-05-27
RS20050002A (en) 2007-09-21
EP1531810B1 (en) 2012-02-01
MXPA05000279A (en) 2005-03-31
AU2003248861B2 (en) 2009-01-22
KR20050025951A (en) 2005-03-14
BR0312503A (en) 2007-06-26
NO20045529L (en) 2005-02-03
CA2490972C (en) 2012-05-29
CN1665500A (en) 2005-09-07
HRP20050001A2 (en) 2005-08-31
AU2003248861A1 (en) 2004-01-23
US20050119312A1 (en) 2005-06-02
JP2006501187A (en) 2006-01-12
WO2004004655A2 (en) 2004-01-15
WO2004004655A3 (en) 2004-10-14
ZA200500029B (en) 2006-06-28
IL165809A (en) 2010-05-17
PL375230A1 (en) 2005-11-28
IL165809A0 (en) 2006-01-15
RU2005103395A (en) 2005-08-10
NO329328B1 (en) 2010-09-27
EP1531810A4 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
ATE543497T1 (en) SUBSTITUTED HETEROCYCLIC DERIVATIVES AS AGENT AGAINST DIABETES AND OBESITY AND METHODS
DE60308210D1 (en) MEDICAL WASHER
CY2014001I1 (en) COMBINATION OF AZELASTIN AND FLUTICAZONE
ATE510534T1 (en) NALTREXONE HYDROCHLORIDE COMPOSITIONS
BRPI0417717A (en) compound, pharmaceutical composition, and use of a compound
NO20050077L (en) Substituted heterocyclic derivatives useful as anti-diabetic and anti-obesity agents
BR0316496A (en) Quinolin-, isoquinolin-, and quinazolin-oxyalkylamides and their use as fungicides
ATE373665T1 (en) BENZO-CONDENSED HETEROARYLAMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
DE60307334D1 (en) Mineral-filled elastomer composition
RS50629B (en) Amide prodrug of gemcitabine, compositions and use thereof
NO20062629L (en) Oxazole derivatives of tetracklines
CY1107156T1 (en) NEW METHOD OF SYNTHESIS (7-Methoxy-3,4-dihydro-1-naphthalinyl) acetonitrile and application in the synthesis of angomelatin
DE60304928D1 (en) Silica-filled elastomer composition
BRPI0417858A (en) compound, pharmaceutical composition, and use of a pharmaceutical composition
BRPI0500536A (en) Antimicrobial Composition
DK1545548T3 (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
DK1558580T3 (en) N-sulfonyl-4-methylamino-3-hydroxy-2-pyridones
ECSP044971A (en) ISOXAZOLOPIRIDINONAS AND ITS USE IN PARKINSON'S DISEASE TREATMENT
SM200300009B (en) Composition and its therapeutic use
DE60321641D1 (en) Photopolymerizable initiator combination and photopolymerizable composition
ECSP056174A (en) USEFUL HYDROXAMIC ACIDS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
ATE371662T1 (en) SILICON COMPOUNDS AND THEIR USE
DE50313185D1 (en) 2-PYRROLIDIN-2-YL-Ä1,3,4Ü -OXADIAZOLE DERIVATIVES AND THEIR USE AS ANTIDEPRESSIVA
BR0316544A (en) Calcally Compounds
ATE456568T1 (en) CONDENSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIDEPRESSANTS